New Jersey Medicaid GLP-1 Coverage (2026): Pattern #11 — Dual-Authority Explicit Exclusion (N.J.A.C. § 10:51-1.13 + 42 U.S.C. § 1396r-8(d)(2)(A) + DMAHS Nov 2025 Memo) + Unprecedented Fiscal Transparency ($37.5M Current / $208.3M Full Coverage / $37.7M Net State-Fund Increase) + SHBP Inverse Coverage Contradiction

New Jersey Medicaid — branded NJ FamilyCare, administered by the NJ Department of Human Services, Division of Medical Assistance and Health Services (DMAHS) for approximately 1.83 million enrollees — is the most transparently-modeled and most actively-debated GLP-1 coverage state in the 11-state Medicaid series to date. It is also the only state in the series with a DMAHS-published fiscal-impact memo to the Legislature specifying dollar projections for full coverage — and the only state where the state-employee plan covers weight-loss GLP-1s while Medicaid categorically excludes them.

This article documents the primary sources behind that exclusion, the three non-weight-loss carve-outs that do exist (Wegovy MACE, Wegovy MASH, Zepbound OSA), the three-session legislative trajectory toward a potential reversal, and the appeal pathway through the NJ Office of Administrative Law.

TL;DR: dual-authority explicit exclusion + unprecedented fiscal transparency

• NJ FamilyCare does NOT cover Wegovy, Zepbound, Saxenda, or Foundayo for the FDA-approved chronic-weight-management indication in adults.
• The exclusion is dual-authority: anchored in N.J.A.C. § 10:51-1.13(a)(2) state regulation and 42 U.S.C. § 1396r-8(d)(2)(A) federal optional-exclusion authority and confirmed operationally by the November 2025 DMAHS GLP-1 Memo to the Legislature.
• NJ FamilyCare does cover GLP-1 receptor agonists for T2D (PA required), Wegovy for cardiovascular disease risk reduction (DURB-approved MACE protocol), Wegovy for noncirrhotic MASH (DURB-approved addendum, October 2025), and Zepbound for obstructive sleep apnea (DURB-approved protocol, July 2025).
• NJ is the only state in the 11-state series where a dollar-quantified fiscal-impact analysis has been published by the state agency: $37.5M gross under current policy vs. $208.3M under full coverage; net state-fund increase $37.7M.
• NJ is the inverse of North Carolina: the NJ State Health Benefits Program (SHBP) covers non-diabetic GLP-1s for weight loss ($45/$125 copay tier, effective November 1, 2025) while NJ FamilyCare categorically excludes them. In NC, Medicaid covers GLP-1s for weight loss while the NC State Health Plan terminated coverage.
• Active reversal-direction legislation: A3369 (222nd Legislature) pre-filed for 2026 session — the third consecutive session the same bill has been introduced. Predecessors A5259 (220th) and S2554 (221st) did not advance. We do not predict A3369’s outcome.

Pattern #11 in the 50-state taxonomy: dual-authority explicit exclusion with fiscal transparency

The 11-state Medicaid GLP-1 series has identified the following structural patterns:

New Jersey is positioned closest to New York (Pattern #3) in regulatory architecture — both states have explicit state administrative-code exclusion language + federal optional-exclusion authority. NJ is positioned closest to Pennsylvania (Pattern #7) in non-weight-loss carve-out architecture: both states have DURB/P&T-approved protocols for Wegovy MACE, Wegovy MASH, and Zepbound OSA. NJ differs from both: it is the only state in the cluster with a state-published fiscal-impact memo and the only state with concurrent SHBP weight-loss coverage while Medicaid excludes.

Triple-anchor: N.J.A.C. § 10:51-1.13(a)(2) + 42 U.S.C. § 1396r-8(d)(2)(A) + DMAHS GLP-1 Memo

NJ’s GLP-1 weight-loss exclusion rests on three independently verifiable primary sources.

Anchor 1 — N.J.A.C. § 10:51-1.13(a)(2): state administrative regulation

The canonical NJ Medicaid pharmaceutical-services regulation lists the following as non-covered:

“Antiobesics and anorexiants, with the exception of lipase inhibitors, when used in treatment of obesity”

The same regulation carves out lipase inhibitors with explicit BMI criteria:

“Coverage of lipase inhibitors is limited to obese individuals with a Body Mass Index (BMI) equal to or greater than 27 kg/m² and less than 30 kg/m² with co-morbidities of hypertension, diabetes or dyslipidemia, and obese individuals with a BMI equal to or greater than 30 kg/m² without comorbidities.”

The regulation also explicitly excludes dietary products:

“food supplements, milk modifiers, infant formulas, therapeutic diets, special liquid or powdered diets used in the treatment of obesity are also excluded, with the exception of enteral nutritional products and electrolyte replacement supplements.”

N.J.A.C. § 10:51-1.13(a)(2) is the New Jersey analog to NY 18 NYCRR § 505.3(g)(3), IL 89 IAC § 140.441(b), and OH OAC 5160-9-03(B)(1). The lipase-inhibitor carve-out operationalizes through the ALLI ORAL CAPSULE entry on the May 1, 2026 Statewide PDL (PA; OTC; QL). Prescription-strength orlistat (Xenical 120 mg) is not listed; the lipase-inhibitor exception is effectively OTC-orlistat-only.

Anchor 2 — 42 U.S.C. § 1396r-8(d)(2)(A): federal optional-exclusion authority

Federal law permits, but does not require, states to exclude from Medicaid coverage “agents when used for anorexia, weight loss, or weight gain.” This is the same federal authority invoked by every other explicit-exclusion state in the series. What distinguishes New Jersey is that DMAHS explicitly cited this authority by statute number in the November 2025 GLP-1 Memo — a degree of statutory transparency not found in the prior 10 states’ primary sources.

Anchor 3 — DMAHS November 2025 GLP-1 Memo: operational confirmation

The November 2025 DMAHS Memo to the Legislature confirms the exclusion in plain language while explicitly naming the covered exceptions:

“Under existing federal and state law, NJ FamilyCare already provides coverage of drugs indicated for weight loss in certain limited circumstances. These include when drugs (including Glucagon-like peptide-1 agonists or GLP-1s) are prescribed for FDA-approved indications other than weight loss. For instance, Wegovy is covered when clinically appropriate for cardiovascular disease, and Zepbound is covered for sleep apnea. Coverage of weight loss drugs is also required in certain cases as part of federal requirements to cover Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) services for children.”

This paragraph is the single most authoritative state-published source in this article. It simultaneously confirms the exclusion for adult chronic weight management, names the two carve-out indications (MACE and OSA), and identifies the EPSDT child-coverage pathway. No other state in the 11-state series has published a comparable explicit operational confirmation at the state-agency memo level.

NJ FamilyCare Statewide PDL (effective May 1, 2026): what is and is not listed

The NJ Medicaid-Approved Preferred Drug List effective May 1, 2026 (published at fm.formularynavigator.com) carries the following header:

“New Jersey
Medicaid-Approved
Preferred Drug List
Effective May 1, 2026”

The PDL is updated on or around May 1 and November 1 each year. Readers should verify the current PDL at fm.formularynavigator.com before relying on any specific drug listing.

GLP-1 T2D class: what is listed

The INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS) class on page 28 of the May 1, 2026 Statewide PDL reads verbatim:

“*INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)***
liraglutide subcutaneous solution pen-injector — Victoza — PA; QL
OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR — PA; QL
OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR — PA; QL
OZEMPIC (2 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR — PA; QL”

The Statewide PDL lists only generic liraglutide (Victoza) and three Ozempic strengths in this class. Mounjaro, Trulicity, Rybelsus, Bydureon BCise, Soliqua, and Xultophy do not appear in this class on the Statewide PDL — but are covered under the MCO-level PDLs and under the DURB-approved GLP-1RA T2D protocol (see below). The Statewide PDL is one layer of a multi-tier coverage architecture; the DURB protocols are the binding clinical-criteria layer.

Lipase inhibitors: what is listed

“*LIPASE INHIBITORS***
ALLI ORAL CAPSULE — PA; OTC; QL”

ALLI (OTC orlistat 60 mg) is the only lipase inhibitor on the May 1, 2026 Statewide PDL. Xenical (prescription orlistat 120 mg) is absent. This is consistent with N.J.A.C. § 10:51-1.13’s narrow lipase-inhibitor exception.

Drugs absent from the May 1, 2026 Statewide PDL (verified)

The following drugs do not appear anywhere in the May 1, 2026 Statewide PDL (verified by exhaustive search of the 7,074-line PDL text on 2026-05-10):

• WEGOVY (semaglutide 2.4 mg) — not listed on the Statewide PDL. Wegovy IS listed on the UHC Community Plan NJ FamilyCare PDL (Tier 2; PA; QL) under “Anti-Obesity Agents — Drugs for Weight Loss” — but that listing is for the non-weight-loss indications (MACE, MASH) only. See the YMYL trap note below.
• ZEPBOUND (tirzepatide for weight management or OSA) — not listed on the Statewide PDL. Zepbound is covered for OSA via DMAHS confirmation (November 2025 GLP-1 Memo) and the DURB-approved OSA protocol (July 2025).
• SAXENDA (liraglutide 3 mg, adult and adolescent obesity indication) — not listed anywhere on the Statewide PDL. Note: generic liraglutide for T2D is listed. Saxenda is the higher-dose obesity-indicated formulation and is effectively excluded for adult NJ FamilyCare enrollees.
• FOUNDAYO — not listed. Foundayo is a LillyDirect cash-pay tirzepatide brand that does not bill insurance; NJ FamilyCare coverage status is not applicable.
• MOUNJARO (tirzepatide for T2D) — not listed on the Statewide PDL but IS covered under the DURB-approved GLP-1RA T2D protocol and on the UHC Community Plan NJ FamilyCare PDL (Tier 2; PA; QL).
• QSYMIA, CONTRAVE — excluded by N.J.A.C. § 10:51-1.13(a)(2) as antiobesics.

YMYL trap — read carefully: The UHC Community Plan NJ FamilyCare PDL (April 1, 2026) lists Wegovy under “Anti-Obesity Agents — Drugs for Weight Loss” as Tier 2; PA; QL. The same PDL’s plan exclusions block lists “Anti-obesity agents” as a categorical exclusion. This is the same structural paradox documented in the IL Meridian/YouthCare PDL and the PA January 2026 Non-Preferred PDL: the Wegovy formulary listing exists because Wegovy has FDA non-weight-loss indications (MACE, MASH), not because NJ FamilyCare covers Wegovy for chronic weight management. Do not read a Wegovy PDL listing as obesity-indication coverage.

DURB-approved non-weight-loss GLP-1 protocols

The NJ Drug Utilization Review Board is DMAHS’s clinical-policy advisory body. It meets quarterly and publishes meeting transcripts, summaries, and approved drug-class protocols at nj.gov/humanservices/dmahs/boards/durb/. NJ is the only state in the 11-state series that publishes verbatim DURB meeting transcripts — granting primary-source access to on-the-record clinical-board deliberation.

GLP-1RA T2D protocol (July 2025 addendum)

The DURB-approved GLP-1RA T2D protocol (original approval October 2022 and January 2023; Commissioner approval February 7, 2024; July 2025 addendum) covers the following drugs for T2D:

“Adlyxin® (lixisenatide)
Bydureon®, Bydureon Pen®, Bydureon Bcise® (exenatide microspheres)
Exenatide
Mounjaro® (tirzepatide)
Ozempic® (semaglutide)
Rybelsus® (semaglutide)
Soliqua™ (insulin glargine/lixisenatide)
Trulicity® (dulaglutide)
Victoza® (liraglutide) – 10 years of age
Xultophy® (insulin degludec/liraglutide)
Protocol applies to FDA approved biosimilars and related indications and dosages”

The verbatim criteria for initial approval include:

“1. Patient is of the FDA-labeled or compendial approved age

2. Patient does not have any contraindications to therapy

3. Patient is not using requested medication concurrently with other GLP-1 (glucagon-like peptide-1) agonists

4. Documentation of HbA1C ≥ 7 measured within the past 6 months is provided

5. Patient has one of the following:
  a. Requests for type 2 diabetes mellitus must meet (i) and (ii)
    i. Confirmed diagnosis of type 2 diabetes mellitus
    ii. Patient has had suboptimal response to metformin therapy (for at least 3 months) or cannot use metformin for one of the following reasons: [Crohn’s Disease, IBS, UC; severe renal impairment eGFR < 45; intolerance or contraindication to metformin]
  b. Requests to reduce the risk of major adverse cardiovascular events must meet (i.) and (ii.)
    i. Confirmed diagnosis of type 2 diabetes mellitus
    ii. Established cardiovascular disease patient has a diagnosis of type 2 diabetes mellitus and atherosclerotic cardiovascular disease (ASCVD) or heart failure, irrespective of metformin use
  c. Requests to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death must meet (i.) and (ii.)
    i. Confirmed diagnosis of type 2 diabetes mellitus
    ii. Documentation of chronic kidney disease is provided”

Important framing: This protocol covers MACE reduction and CKD/cardiovascular-death pathways only when there is a confirmed diagnosis of type 2 diabetes mellitus. Wegovy MACE without T2D is covered through a separate Wegovy MACE protocol (see below); the MACE indication for a non-T2D patient does NOT proceed through the GLP-1RA T2D protocol.

Wegovy MACE protocol (DURB-approved)

The January 2026 DURB packet’s Summary of Recommendations records verbatim:

“Proposed protocol for Wegovy to reduce the risk of major adverse cardiovascular events (MACE) — The Board recommended the protocol”

The DMAHS November 2025 GLP-1 Memo confirms the operative policy at the state-agency level: “Wegovy is covered when clinically appropriate for cardiovascular disease.” The verbatim per-criterion clinical text of the Wegovy MACE protocol — including BMI thresholds, prior MI/stroke/PAD documentation requirements, and any treatment duration limits — requires direct verification by fetching the protocol PDF from the DURB portal before any quantitative criteria are relied upon. Those criteria are not reproduced in this article because the verbatim protocol PDF was not individually extracted in our verification session.

Comparison with other states: NY imposes a BMI threshold of ≥ 40 for Wegovy MACE (stricter than the FDA label’s ≥ 27); NJ’s BMI threshold is not yet individually verified. OH’s Wegovy MACE BMI threshold matches the FDA label (≥ 27) but explicitly excludes T2D patients (A1C < 6.5% required); the NJ Wegovy MACE protocol’s T2D exclusion status is not individually verified. PA’s Wegovy MACE pathway does not exclude T2D patients.

Wegovy MASH addendum (DURB-approved October 22, 2025)

The January 2026 DURB packet records verbatim:

“Proposed Addendum to Protocol for Wegovy® — The Board recommended approval of the addendum to the Wegovy® protocol. The protocol was updated to include a new FDA approved indication for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and relevant criteria for approval.”

The October 22, 2025 DURB transcript records Dr. David E. Swee (DURB Chair) discussing the MASH addendum with the board:

“David E. Swee M.D.: Now moving on to an update, which probably should be a standing update. It always changes every month, every quarter with one of our GLP-1 agonists, in this case, Wegovy because of the new MASH. I already had patients with MASH, who are getting this. So, this moves fast when science changes because people are always looking for help with this kind of condition.”

The verbatim per-criterion clinical text of the Wegovy MASH addendum — including FIB-4 thresholds, biomarker-imaging combinations (FibroScan / MRE / SWE / ELF), alcohol-use disqualifications, and BMI floors — requires direct verification by fetching the Wegovy MASH addendum PDF from the DURB portal. These criteria are not reproduced in this article because the protocol PDF was not individually extracted in our verification session. For comparison: PA’s Wegovy MASH criteria use ELF score + age-stratified FIB-4 (≥ 1.3 under 65 or ≥ 2.0 at 65+); OH’s MASH criteria use FIB-4 > 1.3 + MRE OR MAST OR FibroScan.

Zepbound OSA protocol (DURB-approved July 16, 2025)

The DURB Meeting Documents for July 16, 2025 record verbatim:

“(B) Proposed Protocol for Zepbound® (tirzepatide) for Obstructive Sleep Apnea (OSA) — Recommended — The Board reviewed a proposed Zepbound® protocol for the treatment of OSA. Dr. Swee stated the continuation criteria can be complicated and cumbersome because as the patient loses weight on Zepbound they may not present with moderate to severe OSA. The Board recommended approval of the protocol.”

The DMAHS November 2025 GLP-1 Memo confirms the operative policy: “Zepbound is covered for sleep apnea.” The verbatim per-criterion clinical text of the Zepbound OSA protocol — including AHI thresholds, polysomnography requirements, BMI floors, CPAP-trial requirements, and continuation weight-loss thresholds — requires direct verification by fetching the Zepbound OSA protocol PDF from the DURB portal.

NJ is the only explicit-exclusion state in the 11-state series that covers Zepbound for OSA. NY does not have a Zepbound OSA pathway. IL does not have a Zepbound OSA pathway. OH does not have a Zepbound OSA pathway. PA does have a Zepbound OSA pathway (BMI ≥ 35 + PAP adherence), making PA and NJ the only two explicit-exclusion states in the cluster with all three carve-outs (MACE + MASH + OSA).

Imcivree (setmelanotide): narrow carve-out

The January 2026 DURB packet records the following Imcivree addendum:

“Proposed addendum to the protocol for Imcivree® (setmelanotide) — The Board recommended approval of the addendum to the Imcivree protocol. The protocol was updated to allow Imcivree for patients 2 years of age and older based on the recent FDA approval. Initial criteria was updated to include the Centers for Disease Control and Prevention (CDC) parameters for obesity. The Board recommended the continuation of therapy criteria be updated to remove the requirement for a specific percentage decrease in body mass index (BMI) to evaluate efficacy.”

Imcivree is an MC4 receptor agonist, not a GLP-1 receptor agonist. It covers monogenic or syndromic obesity (POMC/PCSK1/ LEPR deficiency, Bardet-Biedl syndrome, hypothalamic obesity) — not general adult chronic weight management. The October 2025 update extended pediatric eligibility to age 2+. Imcivree is the only anti-obesity medication with a published NJ Medicaid PA pathway, and it covers only the narrow monogenic/syndromic patient population.

DURB transcript primary sources: on-the-record clinical board deliberation

NJ DURB publishes verbatim meeting transcripts — the only state in the 11-state cluster doing so. Two quotes from the October 22, 2025 transcript are load-bearing for this article.

Dr. Swee: “We’re not doing that. We’re doing it just the more broad indications.”

When the board discussed the Wegovy MASH addendum, Dr. David E. Swee (DURB Chair) confirmed on the record that the DURB is approving GLP-1 protocols for FDA-approved non-obesity indications, not for “strictly plain obesity.” From the October 22, 2025 transcript (lines 717-743):

“David E. Swee M.D.: Now moving on to an update … I already had patients with MASH, who are getting this. So, this moves fast when science changes because people are always looking for help with this kind of condition.”

The DURB Chair’s framing is that the board approves GLP-1 protocols indication-by-indication as FDA adds approvals — not as a path to general obesity coverage. This quote is informal panel discussion, not a formal regulatory pronouncement, and should be contextualized as DURB Chair commentary.

Aetna denial-rate outlier: “more than triple Horizon”

The same October 22, 2025 DURB transcript records Dr. Swee flagging an Aetna Better Health of NJ utilization-management outlier in the ADHD/Anti-Narcolepsy/AntiObesity/Anorexiants class:

“We’ve already discussed Aetna as being an outlier when it comes to things like ADHD, anti-obesity, and anorexiants. They have explanations for why their scores are what they are, but it doesn’t tell me why they’re so much higher, like more than triple Horizon. Which is scary. We need to find out what’s going on there.”

Per the DURB Q1 2025 PA report, Aetna Better Health of NJ shows a denial rate of 19.1% in the ADHD/Anti-Narcolepsy/ AntiObesity/Anorexiants class versus Horizon 4.9%, UHC 3.9%, Wellpoint 10.9%, and Fidelis 10.2%. The DURB has flagged this for follow-up; no causation has been documented by primary source. This article does not speculate about the cause of the Aetna outlier; the on-the-record DURB concern is reported as documented.

Unprecedented fiscal transparency: the DMAHS SFY 2026 cost model

The November 2025 DMAHS GLP-1 Memo was submitted in response to a SFY 2026 enacted state budget directive requiring DMAHS “to complete and submit to the Legislature an examination of the viability and likely cost to the State of providing coverage for such drugs in the NJ FamilyCare Program”. The memo’s fiscal table states verbatim:

“The table below projects the cost of full coverage of drugs for the treatment of weight loss in the NJ FamilyCare program in SFY 2026.”

The memo includes verbatim actuarial caveats:

“Note that these projections, which were generated by actuaries contracted with the Division of Medical Assistance and Health Services, are best guesses, subject to a high degree of uncertainty, and which will be affected by numerous factors. These include: (1) enrollment in NJ FamilyCare, (2) demographic and health trends, (3) the development/uptake of new anti-obesity medications, (4) variability of prior authorization criteria, (5) variability of potential MCO supplemental rebates based on coverage policy (weight loss (higher rebates) or no weight loss), (6) preferred drug list status, and (7) drug market shares (percent utilization of Saxenda vs. Wegovy vs. Zepbound). Note also that these estimates are for SFY 2026 – offering full coverage in SFY 2026 or any future year may have additional costs, driven by program growth and/or medical inflation. These estimates were developed in August 2025 and are subject to change as new information becomes available.”

No other state in the 11-state series has published a comparable DMAHS-level fiscal breakdown. The $37.7M net state-fund increase — not the $208.3M gross figure — is the policy-stakes number, reflecting that manufacturer rebates and federal match absorb $133.1M of the gross increase.

The memo also included verbatim federal-policy context:

“Late in the Biden administration, the federal Centers for Medicare and Medicaid Services (CMS) published proposed rulemaking that would require state Medicaid programs to cover weight loss drugs, including GLP-1s. In April 2025, the Trump administration announced that it was not finalizing this proposal but noted that it may address this topic in future rulemaking. If such a regulation were to be finalized in the future, New Jersey would no longer have discretion in this space but would instead be required to cover weight loss drugs under NJ FamilyCare.”

“The ‘One Big Beautiful Bill Act’ contains numerous changes to reduce federal Medicaid spending. The State will begin to experience the most significant impacts of these cuts starting in SFY27, creating budgetary challenges which may constrain the State’s ability to extend full coverage for anti-obesity medications.”

This article does not predict the trajectory of either the federal rulemaking or the OBBBA implementation. The memo’s framing is reported as documented.

The inverse of North Carolina: SHBP covers weight-loss GLP-1s while NJ FamilyCare excludes them

NJ presents a cross-jurisdictional contradiction that is unique in the 11-state series. The NJ State Health Benefits Program (SHBP) — the state and local government employee health plan administered by the NJ Department of Treasury — covers non-diabetic GLP-1s for weight loss, while NJ FamilyCare categorically excludes them.

SHBP PDC Resolution 2025-11 (September 24, 2025) defines non-diabetic GLP-1s verbatim in footnote 4:

“Non-diabetic GLP-1s refer to glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists indicated for therapeutic use in conditions other than diabetes— primarily for chronic weight management and obesity-related comorbidities—and include, but are not limited to, Zepbound, Wegovy, and Saxenda.”

The operative coverage structure (verbatim, paragraphs 1-2):

“1. As of November 1, 2025, the member co-payment for non-diabetic GLP-1 drugs for weight loss shall be $45 per 30-day prescription in the SHBP Plans. This copayment level will continue for SHBP Plan members prescribed non-diabetic GLP-1 drugs for weight loss until the implementation of a lifestyle management program.

2. Upon implementation of a lifestyle management program designed to support members prescribed non-diabetic GLP-1 drugs for weight loss, the co-payments for SHBP Plan members prescribed such products after that implementation date shall be:
— $45 per 30-day supply while the member is participating in the lifestyle management program; or
— $125 per 30-day supply if the member is not participating in the lifestyle management program.”

Critical distinction: SHBP and NJ FamilyCare are governed by different statutory frameworks (N.J.S.A. 52:14-17.25 et seq. for SHBP vs. N.J.S.A. 30:4D-1 et seq. for Medicaid), funded through different mechanisms (SHBP: self-funded by State + employer + employee premiums; NJ FamilyCare: federally matched), and serve different populations (state and local government employees vs. low-income Medicaid enrollees). SHBP coverage of weight-loss GLP-1s does NOT extend to NJ FamilyCare enrollees.

This is the structural inverse of North Carolina, where Medicaid covers GLP-1s for weight loss while the NC State Health Plan (SHP) terminated coverage by 4-3 board vote effective April 1, 2024 and that termination remains in effect. In NJ, the state-employee plan covers and Medicaid excludes. In NC, Medicaid covers and the state-employee plan does not. Both coexistences are documented by primary source; neither is an editorial judgment.

NJ FamilyCare MCO coverage alignment

Approximately 94% of NJ FamilyCare enrollees receive their pharmacy benefit through one of five contracted managed care organizations. The DMAHS-published GLP-1 Memo, N.J.A.C. § 10:51-1.13, and the DURB-approved protocols bind all five MCOs. MCO-level PDLs supplement the Statewide PDL but cannot be more restrictive than the DMAHS-approved minimum.

UnitedHealthcare Community Plan NJ FamilyCare (351,503 enrollees)

The UHC Community Plan NJ FamilyCare PDL (effective April 1, 2026) lists verbatim in its Plan Exclusions block:

“Plan exclusions
The following drug categories are excluded from coverage under the outpatient pharmacy benefit and are not part of the UnitedHealthcare Community Plan PDL.

• DESI drugs
• Anti-obesity agents
• Experimental / research drugs
• Cosmetic drugs
• Nutritional / diet supplements
• Blood and blood plasma products
• Agents used to promote fertility
• Agents used for erectile dysfunction
• Agents used for cosmetic hair growth
• Drugs from manufacturers that do not participate in the FFS Medicaid Drug Rebate Program
• Diagnostic products
• Medical supplies and DME except as listed”

The same PDL lists in the Misc. Antidiabetic Agents T2D class:

“liraglutide (generic for VICTOZA) - Tier 1; PA; QL
MOUNJARO - Tier 2; PA; QL
OZEMPIC - Tier 2; PA; QL
OZEMPIC (2 MG/DOSE) - Tier 2; PA; QL
RYBELSUS - Tier 2; PA; QL
TRULICITY - Tier 2; PA; QL
VICTOZA (brand for liraglutide) - Tier 2; PA; ST; QL”

Horizon NJ Health (989,777 enrollees — the largest NJ FamilyCare MCO)

Horizon NJ Health’s member-facing Covered Drugs page states verbatim:

“Some medicines are not covered under your pharmacy benefit. This includes, but not limited to, fertility agents, weight loss drugs and erectile dysfunction medicines.”

This is the most explicit MCO-level weight-loss-drug exclusion statement in the state — comparable to the Peach State Health Plan (Georgia) verbatim member PDL exclusion documented in the Georgia brief. Horizon NJ Health’s full Medicaid formulary PDF requires direct headless-browser fetch for GLP-1 entries; the HTML wrapper returned in our verification session.

Aetna, Fidelis, Wellpoint

Aetna Better Health of NJ (111,606 enrollees): drug formulary search tool returned HTTP 403 in our verification session. Individual formulary entries are not verified. The DURB Q1 2025 PA report documents Aetna’s 19.1% denial rate in the ADHD/Anti-Narcolepsy/AntiObesity/Anorexiants class (the Aetna outlier flagged by Dr. Swee, documented above). Fidelis Care NJ (88,941 enrollees) and Wellpoint Community Plan NJ (181,222 enrollees, PBM CarelonRx): current GLP-1 formulary entries are not individually verified for this article. All three MCOs are bound by the Statewide PDL, the DMAHS GLP-1 Memo, and the DURB-approved protocols.

T2D vs. weight-loss distinction: the critical clinical boundary

The same molecule (semaglutide) is sold as Ozempic (T2D indication) and Wegovy (chronic weight management, MACE, MASH indications). NJ FamilyCare covers Ozempic for T2D (under the GLP-1RA T2D protocol); NJ FamilyCare does NOT cover Wegovy for chronic weight management.

The clinical boundary matters for three patient types:

• T2D patient prescribed Ozempic for glycemic control: Covered under the GLP-1RA T2D protocol (HbA1C ≥ 7, metformin suboptimal response or contraindication, PA required).
• Patient with established cardiovascular disease and overweight/obesity but no T2D, prescribed Wegovy for MACE risk reduction: Potentially covered under the DURB-approved Wegovy MACE protocol (exact criteria require direct protocol fetch; policy-level confirmation from DMAHS Memo).
• Patient with obesity only (no T2D, no CVD, no MASH, no OSA) prescribed Wegovy or Zepbound for weight management: Not covered. The N.J.A.C. § 10:51-1.13(a)(2) regulatory exclusion applies. No PA pathway exists; an OAL fair hearing cannot override the regulation.

Who does not have a GLP-1 coverage path under NJ FamilyCare

The following NJ FamilyCare populations have no published pathway to GLP-1 receptor agonist coverage for chronic weight management:

• Adult NJ FamilyCare enrollees with BMI ≥ 30 (no comorbidities) seeking Wegovy, Zepbound, or Saxenda for chronic weight management — excluded by N.J.A.C. § 10:51-1.13(a)(2) and confirmed by the DMAHS GLP-1 Memo.
• Adult NJ FamilyCare enrollees with BMI ≥ 27 plus a comorbidity (diabetes, hypertension, dyslipidemia) seeking Wegovy, Zepbound, or Saxenda for chronic weight management — same exclusion. The GLP-1RA T2D protocol covers the T2D indication only, not obesity.
• Adult NJ FamilyCare enrollees seeking Saxenda for any indication — not covered. Saxenda (liraglutide 3 mg) has no DURB-approved non-weight-loss carve-out; the GLP-1RA T2D protocol uses generic liraglutide/Victoza, not Saxenda.
• Pediatric NJ FamilyCare enrollees seeking Saxenda for adolescent obesity (BMI ≥ 95th percentile, ages 12–17) — the EPSDT pathway is theoretically available (confirmed by DMAHS Memo) but is subject to individual case-by-case PA review. Whether Saxenda has historically been approved through EPSDT individual PA review in NJ requires independent verification via DMAHS EPSDT documentation.
• Foundayo users — not a coverage question. Foundayo does not bill insurance.

Legislative trajectory: A3369 and the three-session pattern

The following bill is currently pending in the NJ Legislature:

“ASSEMBLY, No. 3369
STATE OF NEW JERSEY
222nd LEGISLATURE
PRE-FILED FOR INTRODUCTION IN THE 2026 SESSION

Sponsored by:
Assemblyman STERLEY S. STANLEY
District 18 (Middlesex)

Co-Sponsored by:
Assemblywomen Reynolds-Jackson and Speight

SYNOPSIS: Requires SHBP, SEHBP, Medicaid, and NJ FamilyCare to cover anti-obesity medications.”

A3369’s Medicaid/NJ FamilyCare-binding section (verbatim Section 3(a)-(c)):

“3. a. The Medicaid program and the NJ FamilyCare program shall provide coverage for anti-obesity medications under the following circumstances:

(1) the enrollee has a diagnosis of obesity or an obesity-related medical condition from a duly certified or licensed health care provider;
(2) the enrollee is prescribed the anti-obesity medication by a duly certified or licensed physician, physician’s assistant, or advanced practice nurse within the scope of practice; and
(3) the prescribed anti-obesity medication is dispensed by a retail or mail-order pharmacy that is an approved Medicaid pharmacy.

b. The Commissioner of Human Services shall apply for such federal waivers or state plan amendments as are necessary to implement the provisions of this section and to continue to secure federal financial participation for the State Medicaid program and the Children’s Health Insurance Program.

c. Coverage of anti-obesity medications under the Medicaid program and the NJ FamilyCare program, pursuant to this section, is contingent upon federal approval of the State’s application for a waiver or a state plan amendment under Title XIX of the Social Security Act (42 U.S.C. s.1315 et seq.).”

Critical YMYL framing: Section 3(c) explicitly conditions coverage on federal Title XIX waiver or state plan amendment approval. Even if A3369 is enacted, NJ FamilyCare GLP-1 obesity coverage activation is not automatic — it requires CMS approval. We do not predict A3369’s legislative outcome.

A3369 is the third consecutive session the same bill text has been pre-filed:

The three-session pattern is evidence of sustained legislative interest. Both predecessor bills (A5259 and S2554) did not advance to floor passage. This article reports the pattern as documented; we do not predict whether A3369 will advance differently.

How NJ compares with the other 10 states in the series

NJ has the broadest non-weight-loss-indication carve-out menu of any explicit-exclusion state in the series — Wegovy MACE + Wegovy MASH + Zepbound OSA. IL has no carve-outs. NY has only MACE. OH has MACE + MASH but not OSA. PA has MACE + MASH + OSA (same breadth as NJ), but PA is a terminated- coverage state rather than an always-excluded state.

Patient action steps

Step 1: Confirm your NJ FamilyCare plan

Confirm your current NJ FamilyCare MCO enrollment (Aetna, Fidelis, Horizon, UHC Community Plan, or Wellpoint) or whether you are in fee-for-service (FFS). Your member ID card identifies your plan. MCO PA contact information differs by plan; FFS PA routes through NJMMIS.

Step 2: Identify which indication applies

If you have T2D: Ozempic, Mounjaro, Rybelsus, Trulicity, or Victoza may be covered under the GLP-1RA T2D protocol (HbA1C ≥ 7, metformin step-therapy or documented contraindication). If you have established cardiovascular disease and overweight/obesity: ask your prescriber about the DURB-approved Wegovy MACE pathway. If you have noncirrhotic MASH: ask your prescriber about the DURB-approved Wegovy MASH pathway. If you have moderate-to-severe obstructive sleep apnea: ask your prescriber about the DURB-approved Zepbound OSA pathway.

If you have obesity only — no T2D, no established CVD, no MASH, no OSA — there is no current NJ FamilyCare coverage pathway for GLP-1 receptor agonists for chronic weight management. The regulatory exclusion at N.J.A.C. § 10:51-1.13(a)(2) applies.

Step 3: Submit the PA request

PA requests flow through your MCO’s PBM. Verify the specific PA form and submission contact for your plan by visiting your MCO’s provider portal or calling your plan’s pharmacy PA line. Bring the verbatim DURB protocol criteria to your prescriber appointment so the clinical documentation matches the approval criteria.

Step 4: Gather documentation

For the T2D pathway: HbA1C ≥ 7 within the past 6 months, T2D diagnosis, and documentation of metformin suboptimal response or a qualifying contraindication. For the MACE pathway: documentation of established cardiovascular disease (exact criteria require direct DURB protocol PDF fetch). For the MASH pathway: MASH staging documentation (exact biomarker and imaging requirements require direct DURB protocol PDF fetch). For the OSA pathway: polysomnography or equivalent sleep study with AHI score (exact threshold and imaging requirements require direct DURB protocol PDF fetch).

Appealing a PA denial: NJ Office of Administrative Law (OAL)

NJ Medicaid PA denials follow a structured appeal process anchored in N.J.A.C. 10:49 (Manual for Medical Assistance) and N.J.A.C. 1:1 (Office of Administrative Law general rules):

1. MCO internal appeal: For MCO-administered claims, appeal through the MCO’s internal grievance process (typical 30-day decision window, but verify with your MCO).
2. DMAHS Fair Hearing request: Within 20 calendar days of the MCO adverse decision (or within 10 calendar days if you want benefits to continue during the appeal), file a Fair Hearing request with DMAHS. Mailing address: Division of Medical Assistance and Health Services, Fair Hearing Unit, P.O. Box 712, Trenton, NJ 08625.
3. OAL ALJ hearing: DMAHS submits the Fair Hearing request to the NJ Office of Administrative Law within 20 days. An impartial Administrative Law Judge (ALJ) hears the case.
4. DMAHS final agency decision: DMAHS has 45 days from the OAL decision to issue a final agency decision (adopt, modify, or reject the ALJ recommendation).
5. Appellate Division of NJ Superior Court: The enrollee may appeal the DMAHS final decision to the Appellate Division within 45 days.

YMYL framing on the appeal scope: The appeal pathway is a real route for an NJ FamilyCare enrollee whose Wegovy MACE, Wegovy MASH, or Zepbound OSA PA was denied on clinical grounds (e.g., the MCO misapplied criteria, documentation was complete but not recognized). Appeals can succeed in those situations if criteria are met and documentation is complete.

The appeal pathway is NOT a route around the N.J.A.C. § 10:51-1.13(a)(2) regulatory exclusion itself. An NJ FamilyCare enrollee seeking Wegovy for chronic weight management (with no MACE, MASH, or OSA diagnosis) cannot win an OAL fair hearing appeal, because the ALJ cannot override an administrative code regulation. Overriding the regulation would require a regulatory amendment by DMAHS or legislative action such as A3369’s enactment.

KFF January 2026 context

KFF’s January 2026 tracker classifies New Jersey as NOT among the 13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service. NJ is also NOT among the four states that eliminated coverage (CA, NH, PA, SC). NJ is in the larger group of states that have never covered GLP-1s for obesity under Medicaid FFS.

The KFF tracker places Illinois among the 13 covering states — a classification inconsistent with our Illinois brief (Anchor #5), which classified IL as an explicit-exclusion state via 89 IAC § 140.441(b). This discrepancy has been flagged for investigation in a future article update. KFF should be treated as a tertiary reference, not a primary anchor. The DMAHS GLP-1 Memo and N.J.A.C. § 10:51-1.13 are the primary anchors for NJ’s exclusion classification.

NJ FamilyCare PBM and administrative structure

The NJ FamilyCare pharmacy benefit operates through a multi-tier architecture:

• Statewide PDL platform: FormularyNavigator (Magellan platform) at fm.formularynavigator.com.
• Fiscal agent (FFS + MCO PA reporting): Gainwell Technologies via NJMMIS (the New Jersey Medicaid Management Information System). Note: the dispensing-side FFS PBM clinical PA contractor identity is not independently verified in this article beyond Gainwell and the FormularyNavigator platform; verify via the current DMAHS contract list before relying on specific contact routing.
• MCO-level PBMs: CarelonRx for Wellpoint; OptumRx variants for some MCOs; MCO-specific PBMs for others. Verify your MCO’s PA submission contact before filing.
• DURB clinical-policy advisory body: Meets quarterly; publishes transcripts, summaries, and approved protocols at nj.gov/humanservices/dmahs/boards/durb/.

This architecture is structurally similar to PA (7 MCOs + Statewide PDL + PA criteria binding all MCOs) and OH (6+ MCOs + Gainwell SPBM). It differs from NY (FFS-only NYRx consolidation since April 2023) and CA (Medi-Cal Rx FFS-only since 2022).

Related research in this series

• New York Medicaid (NYRx) GLP-1 coverage and Wegovy MACE pathway (2026) — NJ’s closest structural twin in regulatory architecture: both states have explicit state-administrative-code exclusion language + federal optional-exclusion authority. Key differences: NY consolidated to FFS-only via NYRx in April 2023; NJ retains five MCOs. NY MACE BMI threshold is ≥ 40 (stricter than the FDA label) with a lifetime 2-attempt cap; NJ’s Wegovy MACE BMI threshold and cap are not yet individually verified. NY does not cover Wegovy for MASH or Zepbound for OSA; NJ covers both.
• Pennsylvania Medicaid GLP-1 coverage (2026): the policy reversal — the closest operational architecture comparator to NJ: both states have 5-7 MCOs, a Statewide PDL with binding DURB/P&T protocols, and the same three carve-out indications (MACE + MASH + OSA). The critical difference: PA terminated obesity coverage on January 1, 2026 after 34 months of providing it; NJ never had obesity coverage to terminate. PA is the inverse-California narrative; NJ is the persistent-exclusion narrative with active reversal-direction legislation.
• North Carolina Medicaid GLP-1 coverage (2026): the double-reversal state — the structural inverse of NJ for the state-plan vs. state-employee-plan cross-coverage contradiction. In NC, Medicaid covers GLP-1s for weight loss (Wegovy Preferred since December 2025 reinstatement) while the NC State Health Plan terminated coverage in April 2024 and that termination remains in effect. In NJ, the SHBP state-employee plan covers GLP-1s for weight loss ($45/$125 copay tier effective November 1, 2025) while NJ FamilyCare Medicaid categorically excludes them. Both cross-jurisdictional contradictions are documented by primary source; neither is an editorial judgment.
• Ohio Medicaid GLP-1 coverage (2026): triple-anchored exclusion + Wegovy MACE/MASH carve-back-in — NJ and OH are the only two explicit-exclusion states in the series with both MACE and MASH carve-outs for Wegovy. OH added both in a single January 7, 2026 P&T action; NJ built them up indication-by-indication via DURB protocol approvals (Wegovy MACE before October 2025; Wegovy MASH October 2025). NJ extends further: NJ also covers Zepbound for OSA (Ohio does not).
• Illinois Medicaid GLP-1 coverage (2026): the strictest exclusion in the series — structural comparison for the regulatory-exclusion architecture. Both IL and NJ have explicit state-administrative-code exclusion language (89 IAC § 140.441(b) and N.J.A.C. § 10:51-1.13(a)(2) respectively). IL is strictly more restrictive: no MACE, MASH, or OSA carve-out; no DURB-equivalent transparency mechanism.
• GLP-1 pricing index: compounded semaglutide and tirzepatide market — for NJ FamilyCare enrollees excluded from Medicaid coverage for chronic weight management, the cash-pay compounded market is the primary access pathway. NJ is the only explicit-exclusion state in the series with a DMAHS-published fiscal-impact model documenting the coverage-policy gap. The pricing index documents the compounded-market context.
• GLP-1 insurance dropped coverage appeal playbook — four-phase appeal logic and cash-pay bridge strategies for NJ FamilyCare PA denials on covered indications (MACE, MASH, OSA, T2D). Note: the playbook applies to covered-indication denials only; it does not apply to the obesity-indication regulatory exclusion, which is not appealable through the OAL fair-hearing process.
• GLP-1 side effects: every question answered — clinical companion for NJ FamilyCare enrollees who obtain GLP-1s through covered indications or cash-pay pathways.
• Foundayo vs. Wegovy vs. Zepbound: full comparison — relevant context for NJ FamilyCare enrollees navigating the weight-management exclusion. Foundayo is a LillyDirect cash-pay brand that does not bill insurance and is therefore not a Medicaid coverage question.

Last verified and sources

Last verified: 2026-05-10. All URLs were verified by direct curl or WebFetch on 2026-05-10. The NJ Medicaid Statewide PDL is updated on or around May 1 and November 1 each year; verify the current PDL at fm.formularynavigator.com before relying on any specific drug listing. A3369 status should be verified at njleg.gov before relying on any legislative status statement.

Items requiring direct primary-source verification before any quantitative criteria are relied upon (not reproduced in this article because the verbatim protocol PDFs were not individually extracted in our verification session):

• Wegovy MACE protocol verbatim criteria (BMI floor, prior MI/stroke/PAD documentation, treatment-attempt limits) — fetch from nj.gov/humanservices/dmahs/boards/durb/.
• Wegovy MASH addendum verbatim criteria (FIB-4 thresholds, biomarker/imaging combinations, alcohol-use disqualifications) — same source.
• Zepbound OSA protocol verbatim criteria (AHI thresholds, polysomnography requirements, CPAP-trial requirements, continuation weight-loss criteria) — same source.
• Aetna Better Health NJ, Fidelis Care NJ, and Wellpoint NJ current GLP-1 formulary entries — verify via each MCO’s provider portal.
• NJ CMS BALANCE Model participation status — verify at cms.gov/priorities/innovation/innovation-models/balance.